September 1st, 2010, by David Pascoe | clinical trials, new treatments, sansrosa
The recruiting manager from Frontage Clinical is looking for participants in the trial they are hosting for rosacea redness. Frontage Clinical in Hackensack, NJ is conducting a research study to evaluate the safety of an investigational topical gel medication for moderate to severe facial redness associated with ROSACEA. All qualified participants will receive at no cost …
August 4th, 2010, by David Pascoe | galderma, sansrosa
In yet more proof that Galderma wants to sit on the drug known as Sansrosa, a new August 2010 Phase II dose finding study has been listed at clinicaltrials.gov. This latest trial will compare Sansrosa, or CD07805/47 as Galderma now calls it, in strengths of 0.5% and 0.18% against a placebo containing just the vehicle gel. A total of 260 patients will be …
July 12th, 2010, by David Pascoe | sansrosa
Signum Biosciences have announced that their first generation “Signal Transduction Modulator” product, AFC Medirepair (Arazine), is now officially available in Japan. From the product web site, the product has some other related products names such as Skin …
July 1st, 2010, by David Pascoe | in the news, oxymetazoline, red face, sansrosa
News across the business web sites today a new company obtaining funding for a patent protected alpha-adrenergic receptor based treatment for the redness of rosacea.
Vicept Therapuetics is based in Malvern in Pennsylvania and is a privately held company.
From Fidelity Biosciences Joins $10M Series A for Vicept Therapeutics
“We are delighted by the strong investor interest in this round of financing which will allow us to …
May 18th, 2010, by David Pascoe | research, sansrosa
In a recent email to Rosacea News, Dr. Eduardo Pérez, VP of Operations at Signum Biosciences has confirmed that SIG990 is undergoing preclinical safety/toxicology testing as required by the FDA before clinical trials can commence. You can see this confirmed at the company’s web site: Pharmaceutical Development Pipeline.
Signum Biosciences has several molecules under development, SIG990 is their lead candidate for rosacea.
Anti-Redness Efficacy of SIG0990
In …
|
|
|
|
|
|
|
|
 |